Philip A. Philip

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Adjuvant Chemotherapy +/- Chemoradiotherapy for Adenocarcinoma of The Pancreatic Head: Results of The Radiotherapy Randomization of NRG Oncology/RTOG 0848

  Journal of Clinical Oncology · 2026-06-09

• Abstract 4579: Preclinical evaluation of a novel hyperbolic NAMPT inhibitor in combination with pan-RAS targeted therapies in pancreatic ductal adenocarcinoma

  Cancer Research · 2026-04-03

• PCNA Inhibition Enhances the Antitumor Activity of KRAS-Targeted Therapies in Pancreatic Cancer

  bioRxiv (Cold Spring Harbor Laboratory) · 2025-12-10

• Targeting KRAS mutations: orchestrating cancer evolution and therapeutic challenges

  Signal Transduction and Targeted Therapy · 2025-11-27 · 28 citations

• PANOVA-3: Phase 3 study of tumor treating fields (TTFields) with gemcitabine and nab-paclitaxel for locally advanced pancreatic ductal adenocarcinoma (LA-PAC).

  Journal of Clinical Oncology · 2025-06-04

• Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study

  Journal of Clinical Oncology · 2025-05-31 · 38 citations

• The differential effect of stromal genes on gemcitabine/nab-paclitaxel (GN) and GN/cisplatin (GCN) outcomes in advanced pancreatic adenocarcinoma (aPDAC).

  Journal of Clinical Oncology · 2025-05-28

• Abstract 6909: Exportin 1 as a novel therapeutic target in gastroenteropancreatic neuroendocrine tumors

  Cancer Research · 2025-04-21

• Abstract 7213: Targeting XPO1 to enhance the durability of response of MRTX1133 in pancreatic ductal adenocarcinoma

  Cancer Research · 2025-04-21

• Abstract 6876: A novel PCNA inhibitor AOH1996 demonstrates pre-clinical efficacy in pancreatic ductal adenocarcinoma models

  Cancer Research · 2025-04-21 · 2 citations

• S2303: phase II/III trial of paclitaxel + ramucirumab ± nivolumab in gastric and esophageal adenocarcinoma (PARAMUNE)

  Future Oncology · 2025-03-28 · 2 citations

• A Phase 1b/2 Study of the Anti-CD47 Antibody Magrolimab with Cetuximab in Patients with Colorectal Cancer and Other Solid Tumors

  Targeted Oncology · 2025-03-26 · 20 citations

• Utilizing Patient Input in Rectal Cancer Trial Design

  JNCI Journal of the National Cancer Institute · 2025-03-19 · 3 citations

• Incorporating Circulating Tumor DNA Testing Into Clinical Trials: A Position Paper by the National Cancer Institute GI Oncology Circulating Tumor DNA Working Group

  JCO Precision Oncology · 2025-03-01 · 3 citations

• Molecular Characterization and Clinical Outcomes of Pancreatic Neuroendocrine Neoplasms Harboring PAK4-NAMPT Alterations

  JCO oncology advances. · 2025-03-01 · 2 citations

• Chemotherapy dose density is prognostic for overall survival in patients with resectable pancreas cancer: A landmark analysis of SWOG 1505

  Cancer · 2025-02-11 · 2 citations

• Trastuzumab Plus Pertuzumab Versus Cetuximab Plus Irinotecan in Patients With <i>RAS/BRAF</i> Wild-Type, HER2-Positive, Metastatic Colorectal Cancer (S1613): A Randomized Phase II Trial

  Journal of Clinical Oncology · 2025-01-06 · 9 citations

• SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers

  Journal of Clinical Oncology · 2024-12-13 · 47 citations

• Targeting mitochondrial metabolism with CPI-613 in chemoresistant ovarian tumors

  Journal of Ovarian Research · 2024-11-14 · 17 citations

• RCC1 regulation of subcellular protein localization via Ran GTPase drives pancreatic ductal adenocarcinoma growth

  Cancer Letters · 2024-09-24 · 6 citations